Low Float (GOVX) Is A Nasdaq Biotech Profile With Backing From 5 Key Potential Catalysts

Did you catch my last breakout idea?

*Sponsored Low Float (GOVX) Is A Nasdaq Biotech Profile With Backing From 5 Key Potential Catalysts March 4th Dear Reader, Did you catch my last breakout idea? A Nasdaq idea alerted late Sunday, it took the markets by storm in pre-market and right after the opening bell. Closing in after-hours this past Friday at $.47, it rocketed quickly to a high of $.8989 to get the week started with a major statement. Overall, the short term surge of approximately 91% was something to soak in with a smile. But it's no time to start patting backs... It's time to focus on what's next. And that's a Nasdaq biotech profile currently flying under Wall Street's radar. That said, with compelling news out Monday, a low float under 9Mn shares, and analysts salivating with significant targets suggesting over 300% potential upside, it may just be a matter of time until the market takes notice of this little-known company. Before that happens, consider this disruptor biotech profile for your watchlist: *GeoVax Labs, Inc. (Nasdaq: GOVX)* GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. And based on several potential catalysts, GOVX could start garnering some serious breakout buzz. Check them out: No. 1 - A Lot Float Could Create a Strong Possibility For Volatility On A Daily Basis. No. 2 - Analyst Targets Point To Serious, Triple-Digit Potential Upside! No. 3 - MVA-Based Vaccines Could Be Absolutely Critical To U.S. Biodefense Strategy. No. 4 - 2025 Could Be A Game-Changing Year As Potential "Catalyst-Rich" Milestones Come Into View. No. 5 - GeoVax Makes Major Announcement To Harness Advanced Tech Like Artificial Intelligence (AI). But more on those in a second... GeoVax Labs, Inc. Company Overview GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation CVD-19 vaccine and therapy for advanced head and neck cancer. Additional development programs include preventive vaccines against M-po-x and sm-all-po-x, hemorrhagic fever viruses, malaria and Z-ika vi-rus, as well as therapies for various solid tumors. At GeoVax, they are guided by the following strategic imperatives as they develop and grow their company: Innovate – Pursuing the development of unique, patented products addressing unmet medical needs Differentiate – Targeting populations underserved by existing products/standard of care Accelerate – Focused on expedited registration pathways Collaborate – Achieve worldwide distribution via business collaborations 2025 Milestones & Catalysts GeoVax Portfolio: Revenue Opp. Grab Sources And More: GOVX Website. GOVX Presentation. ----- As mentioned above, (Nasdaq: GOVX) has several potential catalysts to start considering. Take a look: No. 1 GOVX Potential Catalyst - A Lot Float Could Create a Strong Possibility For Volatility On A Daily Basis. According to info from the Yahoo Finance website, GOVX has a low float. The website reports this profile to have roughly 8.9Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. ----- No. 2 GOVX Potential Catalyst - Analyst Targets Point To Serious, Triple-Digit Potential Upside! MarketBeat is reporting GOVX to have several, significant analyst targets. Take a look: Even the smallest target recorded above displays upside potential over 300% from GOVX's closing valuation on Monday. ----- No. 3 GOVX Potential Catalyst - MVA-Based Vaccines Could Be Absolutely Critical To U.S. Biodefense Strategy. GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy GeoVax's GEO-MVA: Strengthening U.S. Biodefense ATLANTA, GA - March 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in developing vaccines and immunotherapies for infectious diseases and cancer, underscores the strategic importance of its Modified Vaccinia Ankara (MVA) vaccine platform in helping to bolster U.S. biodefense capabilities. Efforts in MVA vaccine design and manufacturing improvements align with key recommendations from the recent "Bolstering U.S. Biodefense: Recommendations For The New Administration" report, published by the Janne E. Nolan Center on Strategic Weapons at the Council on Strategic Risks, a respected think tank specializing in national security and biodefense policy. The report emphasizes the need for robust, diversified medical countermeasures to protect national and global security. ... A Call for Action "The 'Bolstering U.S. Biodefense' report clearly articulates the vulnerabilities in our national health security framework. GeoVax is committed to helping address these gaps with our MVA-based vaccines and next-generation manufacturing capabilities," said David Dodd, Chairman & CEO of GeoVax. "With a new HHS administration, there is a timely opp. to strengthen domestic vaccine infrastructure and ensure greater national resilience against emerging threats." ... Read the full article here. ----- No. 4 GOVX Potential Catalyst - 2025 Could Be A Game-Changing Year As Potential "Catalyst-Rich" Milestones Come Into View. GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs Strategic Progress Across CVD-19, M-po-x, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum ATLANTA, GA - February 5, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today outlined its 2025 strategic milestones and business outlook. Building on a history of delivering on key commitments, GeoVax enters 2025 with a robust pipeline, a catalyst-rich milestone schedule, and an unwavering commitment to addressing unmet medical needs on a global scale. ... David Dodd, Chairman & CEO of GeoVax, commented: "2024 was a transformative year for GeoVax, and our focus and commitment in 2025 is unwavering, focused on critically needed unmet medical needs. Our pipeline, enriched with value-driven milestones, positions us well for successful growth and development. Collaborations and partnerships remain core to our strategy, ensuring our innovations reach those who need them most. With GEO-CM04S1, GEO-MVA, Gedeptin, our MVA manufacturing advancements, and leveraging AI to optimize our processes and drive innovation, we are prepared to make meaningful contributions to global health, delivering value to our fellow shareholders, various stakeholders and, providing compelling career development opp's to our staff colleagues." ... Read the full article here. ----- No. 5 GOVX Potential Catalyst - GeoVax Makes Major Announcement To Harness Advanced Tech Like Artificial Intelligence (AI). GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative Harnessing AI to Revolutionize Vaccine and Therapy Development ATLANTA, GA - February 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J. Trump's Stargate Initiative, which aims to harness advanced technologies including Artificial Intelligence (AI) to strengthen U.S. healthcare, biosecurity, and global innovation leadership. This announcement aligns with GeoVax's commitment to leveraging AI across its vaccine and cancer immunotherapy programs to accelerate research, optimize operations, and deliver life-saving solutions. ... David Dodd, GeoVax Chairman and CEO, stated: "President Trump's Stargate Initiative exemplifies leadership in harnessing AI to address critical healthcare challenges. GeoVax is honored to support this initiative, highlighting its application of AI to develop vaccines and therapies that save lives and enhance biosecurity. We are proud to contribute to a future where the United States leads the world in healthcare innovation." Read the full article here. ----- (Nasdaq: GOVX) Recap - 5 Potential Catalysts Lead The Way No. 1 - A Lot Float Could Create a Strong Possibility For Volatility On A Daily Basis. No. 2 - Analyst Targets Point To Serious, Triple-Digit Potential Upside! No. 3 - MVA-Based Vaccines Could Be Absolutely Critical To U.S. Biodefense Strategy. No. 4 - 2025 Could Be A Game-Changing Year As Potential "Catalyst-Rich" Milestones Come Into View. No. 5 - GeoVax Makes Major Announcement To Harness Advanced Tech Like Artificial Intelligence (AI). ----- Coverage is officially initiated on GeoVax Labs, Inc. (Nasdaq: GOVX). I'll be in touch with reminders/updates soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/03/2025 and ending on 03/04/2025 to publicly disseminate information about (GOVX:US) via digital communications. Under this agreement, SWN Media LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (GOVX:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/govx/#details

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice